首页 › 基金 › Defilade Capital Management, L.P. › CRNX

Defilade Capital Management, L.P. 对 CRNX 的持仓历史

CRINETICS PHARMACEUTICALS IN

Defilade Capital Management, L.P. 在 Q2 2026 的 13F 申报中披露持有 CRNX(CRINETICS PHARMACEUTICALS IN)239,440 股,市值约 US$9.0M,约占其申报组合的 1.20%,在其申报持仓中市值排名第 36 位。 Defilade Capital Management, L.P. 于 Q2 2026 首次申报该持仓。

最新持仓 (Q2 2026)239.44K 股
申报持仓市值$8.96M
组合权重1.20%
首次申报Q2 2026
最近变动新进
更新于2026-10-24

最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR

Defilade Capital Management, L.P. 对 CRNX 的持仓演变

Defilade Capital Management, L.P. 于 Q2 2026 首次披露 CRNX 持仓:239,440 股(约 US$9.0M)。

逐季持仓明细

季度股数金额变化
Q2 2026 239.44K $8.96M 新进

关于 CRNX 与 13F 数据

CRNX(CRINETICS PHARMACEUTICALS IN)的行业分类暂缺。我们追踪的基金中还有 38 只申报持有 CRNX,申报仓位最大的包括:法拉龙资本管理 (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 CRNX 的基金

查看 CRNX 的全部基金持有人 →

常见问题

How long has Defilade Capital Management, L.P. held CRNX?

Defilade Capital Management, L.P. has disclosed CRNX holdings in 1 of the last 1 reported quarters, going back to Q2 2026.

What is Defilade Capital Management, L.P.'s current position in CRNX?

As of Q2 2026, Defilade Capital Management, L.P. holds 239.44K shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $8.96M, representing 1.20% of its reported portfolio and ranking #36.

Has Defilade Capital Management, L.P. been buying or selling CRNX?

In the latest 13F filing (Q2 2026), Defilade Capital Management, L.P. newly opened its position in CRNX.

Which other funds hold CRNX?

Other major institutional holders of CRNX include 法拉龙资本管理, FARALLON CAPITAL MANAGEMENT, L.L.C., DRIEHAUS CAPITAL MANAGEMENT LLC, among 38 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.